SLC43A1
Large neutral amino acids transporter small subunit 3
Protein Summary
Sodium-independent, high affinity transport of large neutral amino acids. Has narrower substrate selectivity compared to SLC7A5 and SLC7A8 and mainly transports branched-chain amino acids and phenylalanine. Plays a role in the development of human prostate cancer, from prostatic intraepithelial neoplasia to invasive prostate cancer. SLC43A1 belongs to the system L family of plasma membrane carrier proteins that transports large neutral amino acids (Babu et al., 2003 [PubMed 12930836]).[supplied by OMIM, Mar 2008]
- ENST00000278426
- ENSP00000278426
- ENSG00000149150
- ENST00000528450
- ENSP00000435673
- LAT3
- PB39
- POV1
- LAT3
- PB39
- POV1
- R00504
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
gene perturbation | 0.89 | ||
PubMedID | 0.73 | ||
transcription factor binding site profile | 0.73 | ||
transcription factor | 0.63 | ||
histone modification site profile | 0.62 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 22.73 (req: < 5)
Gene RIFs: 1 (req: <= 3)
Antibodies: 97 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 22.73 (req: >= 5)
Gene RIFs: 1 (req: > 3)
Antibodies: 97 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0